Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
An economic evaluation of eptifibatide
Autore:
Villar, FA; Botella, FA;
Indirizzi:
Univ La Rioja, Dept Econ & Empresa, Logrono 26004, Spain Univ La Rioja Logrono Spain 26004 t Econ & Empresa, Logrono 26004, Spain Hosp San Millan San Pedro, Logrono, Spain Hosp San Millan San Pedro Logrono Spain illan San Pedro, Logrono, Spain
Titolo Testata:
REVISTA ESPANOLA DE CARDIOLOGIA
fascicolo: 2, volume: 54, anno: 2001,
pagine: 169 - 174
SICI:
0300-8932(200102)54:2<169:AEEOE>2.0.ZU;2-G
Fonte:
ISI
Lingua:
SPA
Keywords:
unstable angina; myocardial infarction; economic analysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Villar, FA Univ La Rioja, Dept Econ & Empresa, Ciguena 60, Logrono 26004, Spain Univ La Rioja Ciguena 60 Logrono Spain 26004 rono 26004, Spain
Citazione:
F.A. Villar e F.A. Botella, "An economic evaluation of eptifibatide", REV ESP CAR, 54(2), 2001, pp. 169-174

Abstract

Introduction and objective. The aim of this study was to perform an economic evaluation of the; PURSUIT trial in Spain, and to measure the cost per year of life saved in patients treated with this drug. PURSUIT is a large, randomised multicentric study on the treatment of unstable angina or non Q wave myocardial infarction with eptifibatide versus placebo,Methods. The data on resource consumption provided by the PURSUIT trial were grouped in several populations according to geographical and resource consumption criteria, Unitary costs of these resources were calculated using an <<upward>> approach that combines individual costs to obtain total costsof several processes and lengths of hospital stay. Cost analysis compares the costs of the initial admission and of the following six months (total cost per patient) for both placebo and eptifibatide. Cost-effectiveness analysis is calculated from total costs and years of life saved calculated according to projections made from results of PURSUIT for Western Europe. Results. The average 6 month cost for the patients who received placebo varies from 0.91 to 1.41 million pesetas, and from 0.96 to 1.45 million pesetas for those treated with eptifibatide. The mean survival was 16.07 years in the placebo group versus 16.11 years in eptifibatide group; 2.9 years of life were saved for every 100 patients treated. The incremental cost of each year of life saved ranges from 1.3 to 3.3 million pesetas. Conclusion. Results vary depending on resource consumption data used. The cost per year of life saved is within the limits considered acceptable for a new technology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 03:35:01